First Horizon Advisors, Inc. Mirati Therapeutics, Inc. Transaction History

First Horizon Advisors, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	BUY	$27.8 - $45.35 $9,396 - $15,328	338 Added 89.89%	714 $31,000
Q4 2022 Feb 10, 2023	SELL	$41.27 - $98.62 $4,044 - $9,664	-98 Reduced 20.68%	376 $17,000
Q3 2022 Nov 09, 2022	BUY	$59.5 - $86.7 $5,712 - $8,323	96 Added 25.4%	474 $32,000
Q2 2022 Aug 02, 2022	BUY	$39.16 - $88.71 $14,802 - $33,532	378 New	378 $25,000
Q1 2022 May 10, 2022	SELL	$75.82 - $150.97 $834 - $1,660	-11 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $4,360 - $5,855	-33 Reduced 75.0%	11 $1,000
Q3 2021 Nov 09, 2021	BUY	$132.13 - $177.45 $5,813 - $7,807	44 New	44 $7,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on First Horizon Advisors, Inc. with notifications on news.